As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator »s biologic products. But scientific challenges remain due to the complexity of both the manuf
Achetez cet ebook et obtenez-en 1 de plus GRATUITEMENT !
Format PDF ● Pages 444 ● ISBN 9781466579705 ● Maison d’édition CRC Press ● Publié 2013 ● Téléchargeable 6 fois ● Devise EUR ● ID 2715426 ● Protection contre la copie Adobe DRM
Nécessite un lecteur de livre électronique compatible DRM